Human malignant glioma cells are characterized by local invasion. In the present study, we investigated the role of osteopontin (OPN) in the invasiveness of human glioma cells isolated from grade IV tumors. We found that the expression levels of OPN in these cell lines paralleled matrix metalloproteinase-2 (MMP-2) expression and cell invasiveness potential. When U87MG glioma cells (with a high-OPN expression level) were stably transformed with specific small hairpin RNA to knock down OPN expression, MMP-2 secretion, cell invasiveness, and tumor growth in implanted brains were dramatically reduced. Conversely, forced expression of OPN in GBM-SKH glioma cells (which expressed OPN at a low level) increased MMP-2 secretion, enhanced cell invasiveness, and increased tumor growth in a rodent xenograft model. Expression of OPN was associated with increased expression of vimentin and decreased expression of glial fibrillary acidic protein. Treatment of glioma cells with 5-aza-2′-deoxycytidine (5-aza-dC) suppressed OPN expression in a concentration-dependent manner. Suppression of OPN expression by 5-aza-dC was associated with reductions in MMP-2 secretion, vimentin expression, cell invasion, intravasation, and tumor growth. These data suggest that OPN may play important roles in regulating cell invasion in glioma cells and that 5-aza-dC may serve as a therapeutic agent for human gliomas.
1 January 2015 in Journal of Veterinary Medical Science
This study determined the antimicrobial resistance profiles of Escherichia coli isolates from dogs with a presumptive diagnosis of urinary tract infection (UTI). Urine samples from 201 dogs with UTI diagnosed through clinical examination and urinalysis were processed for isolation of Escherichia coli. Colonies from pure cultures were identified by biochemical reactions (n=114) and were tested for susceptibility to 18 antimicrobials. The two most frequent antimicrobials showing resistance in Urinary E. coli isolates were oxytetracycline and ampicillin. Among the resistant isolates, 17 resistance patterns were observed, with 12 patterns involving multidrug resistance (MDR). Of the 69 tetracycline-resistant E. coli isolates, tet(B) was the predominant resistance determinant and was detected in 50.9% of the isolates, whereas the remaining 25.5% isolates carried the tet(A) determinant. Most ampicillin and/or amoxicillin-resistant E. coli isolates carried blaTEM-1 genes. Class 1 integrons were prevalent (28.9%) and contained previously described gene cassettes that are implicated primarily in resistance to aminoglycosides and trimethoprim (dfrA1, dfrA17-aadA5). Of the 44 quinolone-resistant E. coli isolates, 38 were resistant to nalidixic acid, and 6 were resistant to nalidixic acid, ciprofloxacin and enrofloxacin. Chromosomal point mutations were found in the GyrA (Ser83Leu) and ParC (Ser80Ile) genes. Furthermore, the aminoglycoside resistance gene aacC2, the chloramphenicol resistant gene cmlA and the florfenicol resistant gene floR were also identified. This study revealed an alarming rate of antimicrobial resistance among E. coli isolates from dogs with UTIs.
1 September 2008 in European Journal of Pharmacology
Three experiments were conducted to evaluate the effects of taurine (Tau) supplements on broiler growth performance, serum constituents and antibody production. In Exp. 1, 3 day old chicks received a basal diet supplemented with Tau at 0, 0.10, 0.20, 0.30 or 0.40% for 6 weeks. Although dietary Tau supplementing at 0.30 or 0.40% enhanced feed conversion and reduced feed consumption during 0 to 3 weeks (p<0.05), neither serum total cholesterol or anti-Newcastle disease virus (NDV) titer were affected. In Exp. 2, dietary Tau supplement at 0.25-0.75% enhanced feed conversion of broilers during 0 to 3 weeks, but daily gain and feed consumption were not affected. The 0.75% Tau supplement group displayed lower serum total cholesterol at 6 weeks (p<0.05) comparing with the control group but no difference in anti-NDV titers. In Exp. 3, broilers were treated with dietary Tau of 0 or 0.50% combined with low (0/0%), medium (0.18/0.08%), or high (0.36/0.16%) methionine (Met) levels for 6 weeks (0 to 3/3 to 6 weeks). The addition of Met significantly improved daily gain and feed conversion of broilers during 0 to 3 weeks (p<0.01). Dietary Tau interacted significantly with Met on daily gain and feed consumption. Broiler serum amino acids revealed that Met supplements only increased serum Met level, but only serum Tau level was enhanced as given dietary Tau supplementation. The broilers receiving Tau normalized serum triglycerides level by feeding with the low Met diet and tended to display higher anti-NDV titers (p<0.10). The experimental results suggest that the growth response obtained by Tau supplements results partly from interactions with sulfur amino acids. However, the modulation of the broiler lipid metabolism may be responsible for dietary Tau.